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In order to investigate the effects of protein kinase C (PKC) expression on cellular growth and morphology, we established mouse fibrobiast cell 
pop~ations which expressed the rat pkc-y gene under the control of a retroviral promoter. NIH 3T3 stable ~nsf~tants displayed a three-fold 
increase in total PKC levels. These cells appeared mo~holo~~lly unaltered but exhibited a stronger mitogenic response to 12~0)-tetradecanoyl- 
phorbol-13-acetate (TPA) and cardiolipin (CL) as well as enhanced growth in semisolid medium in the presence of TPA. Thus, at these enzyme 
levels, PKC conferred growth advantages to NIH 3T3 cells only in response to specific activators. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Protein kinase C (PKC), as described by Nishizuka 
and colleagues (reviewed in [ 1,2]), consists of a family 
of Ca2 ’ and phospholipid-dependent serine-threonine 
kinases which exhibit strong amino acid sequence 
homology and structural similarity [3-51. Diacyl- 
glycerol (DAG) is an endogenous activator of different 
subspecies including types I, II and III [6]. An early 
event in signal transduction is an increase in the 
hydrolysis of phosphatidyl inositol 2,4 bisphosphate 
[7,8], yielding phosphoinositol 1,4,5 trisphosphate 
(IP3) and DAG. The fact that many growth factors in- 
duce an increase in DAG has led to the speculation that 
PKC plays a pivotal role in the mechanism of signal 
transduction 191. On the other hand, there are indica- 
tions that PKC might not be necessary for the transmis- 
sion of some growth signals [lo-121. Moreover, over- 
production of PKC in two different cell types induced 
varying degrees of morphological changes [13,14] 
which ranged from subtle differences in growth [14] to 
focus formation and anchorage independence 1131. 
In order to further define the effect of PKC expres- 
sion on cell growth and morphology, we transfected the 
gene coding for rat PKC-I into NIH 3T3 cells. The 
response of these cells to specific activators of PKC was 
analyzed with respect o mitogenic activity and cloning 
efficiency. 
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2.1. Ptasmids 
The 2.2. kb NcoI-XbaI fr~ment ~ont~ning the full coding se- 
quence of rat pkc-y was isolated from PMT 2-PKCI 19 and subcloned 
into the BumHI site of vectors CIX-I and LTR-2 to yield the con- 
structs pAC20 and pAC24, respectively. CIX-I was generated from 
pLJ [Iti] by removing the 1.4 kb DruI fragment which inactivates the 
polyoma middle T gene. Plasmids LTR-2 and pSV2neo have been 
described [16,17]. 
2.2. Analysis of PKC expression 
The relative level of endogenous and transfected PKC was deter- 
mined by Western blot analysis [18] using specific antibodies. 
Polyclonal antisera directed against either PKC-I (7) or PKC-II co) 
were a gift of Dr. B. Straulovic (Syntex). Tumor cell line HA1984 
which overexpresses PKC-II was a gift of Dr. S. Aaronson. PKC-III 
(CY) was identified with antibody MC5 (Amersham) which did not 
recognize the PKC-I isoform (data not shown). 
2.3. PDBu binding 
Cells were plated in 1 cm wells in triplicate and allowed to pro- 
liferate until confluence. They were washed three times with DMEM 
and after incubation for 30 min, DMEM containing 50 nM [‘H]PDBu 
(26.6 Ci/mmol, Amersham) was added at 37°C for 1 h. Cells were 
rinsed twice with PBS and twice with cold 5% TCA. TCA insoluble 
material was resuspended in 0.25 N NaOH and the amount of bound 
[‘H]PDBu was correlated to the number of cells in replica wells. 
2.4. Cell culture 
Growth of NIH 3T3 cells and calcium-phosphate ransfections were 
conducted as described elsewhere 1191. Cetls were selected with killer 
HAT medium or medium supplemented with 0.5 mg/ml G418 (Gib- 
co). For agar growth assays, cells were resuspended in medium con- 
taining 0.3% agar (Difco) [20]. TPA (Sigma) was added at the in- 
dicated concentrations. Mitogenic assays were performed as described 
in [21]. Medium was supplemented with TPA or cardiolipin (Sigma) 
plus 3 &i/mm01 of [‘Hlthymidine (50-W mCi/mmol, New England 
Nuclear). 
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3. RESULTS 
3.1. Transfection of expression vectors containing the 
rat pkc-y gene into NIH 3T3 cells does not induce 
the transformed phenotype 
Expression of PKC-I with the help of the adenovirus 
late promoter has been reported for COS cells [3]. In 
order to achieve higher expression levels in murine 
fibroblasts the complete coding sequence of pkc-y was 
placed under the control of the LTR sequences of the 
Moloney murine leukemia virus, yielding plasmids 
pAC20 and pAC24, respectively (fig. 1). Plasmids 
PMT2-PKCI, pAC20 and pAC24 were transfected into 
NIH 3T3 cells using lo-O.01 ,ug DNA per plate. 
PMTZPKCI plasmid DNA was cotransfected with 
pSV2neo DNA at a 1O:l molar ratio. 
These PKC constructs did not induce transformed 
foci beyond the rate of spontaneous focus formation 
measured in cells transfected with vector DNAs alone. 
It has been suggested that alterations in growth of NIH 
3T3 cells are dectectable only in the absence of non- 
transfected cells [14]. We, therefore, screened trans- 
fected cells grown under selective pressure for mor- 
phological changes. No reproducible differences in 
phenotypes could be detected when compared to cells 
transfected with vector DNAs only. 
3.2. Expression of the rat pkc-y gene in transfected 
NIH 3T3 cells leads to a three-fold increase in the 
total number of phorbol ester receptors 
We estimated the expression levels of PKC-I in these 
cells by Western blot analysis. As shown in fig.2, NIH 
3T3 cells transfected with vector DNAs alone did not 
express the PKC-I or PKC-II isoforms. However, the 
cell populations which contained either one of the three 
different pkc-y plasmids produced easily detectable 
levels of PKC-I. Thus, whereas NIH 3T3 cells contain 
only PKC-III, rat PKC-I can be efficiently expressed in 
these cells without changing cellular morphology. 
Since PKC-I and PKC-III bind DAG or phorbol 
esters with similar affinities [22], binding of PDBu to 
cells which express PKC-I and endogenous PKC-III can 
be used to estimate the increase in the total level PKC 
enzyme. The additional presence of PKC-I led to a two- 
to three-fold increase in total number of high affinity 
receptors for PDBu (table 1). 
3.3. Production of PKC-I in NIH 3T3 transfectants 
results in an increased mitogenic response to 
specific enzyme activators 
Phorbol esters act as mitogens in several cell systems 
via activation of PKC [2,6]. We compared the 
mitogenic response which could be elicited by different 
concentrations of TPA in pkc-y transfectants with that 
of cells transfected with vector DNA only. As shown in 
fig.3A, in the presence of 50-200 nM TPA NIH 3T3 
cells containing pAC24 gave a three- to four-fold larger 
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Hg. 1. Structure of plasmids pAC20 and pAC24. PKC-I is expressed 
under the control of the Monoley murine leukemia virus LTR se- 
quences (MoLTR). The neo and gpt genes were used for selection of 
transfected NIH 3T3 cells. 
mitogenic response than control cells. In addition, we 
analyzed the increase in [3H]thymidine incorporation 
elicited by cardiolipin which has been suggested to 
specifically activate PKC-I [22]. Cardiolipin concentra- 
tions in the range of lo-100 pug/ml also generated an 
enhanced [3H]thymidine incorporation in the pkc-y 
transfectants (fig.3B). 
3.4. Higher PKC levels in NIH 3T3 cells lead to 
increased cloning efficiencies in semisolid medium 
in the presence of TPA 
NIH 3T3 cells transfected with pAC24 grew in 
semisolid medium with similar cloning efficiency as 
cells harboring vector sequences only. As shown in 
table 2, however, in the presence of increasing concen- 
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Fig.2. Analysis of the expression of PKC-I, PKC-II, and PKC-III. 
Western blot analysis was performed with antibodies against PKC-III 
(A), PKC-II (B) and PKC-I (C). 1, cell line 25-41, expressing PKC-I 
from plasmid pAC20; 2, cell line 25-91 containing vector CIX-I; 3, 
cell line 25-61 expressing PKC-I from plasmid pAC24; 4, cell line 
25-77 expressing PKC-I from plasmid PMTZ-PKCI; 5, cell line 25-89 
containing vector LTR-2; 6, tumor cell line HA1984 overexpressing 
PKC-II as determined by Northern blot hybridization (data not 
shown). 
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Fig.3. Mitogenic response to increasing concentrations of TPA (A) 
and cardiolipin (B) of cell line 25-61 expressing PKC-I from plasmid 
pAC24 (0) and of cell line 25-89 transfected with vector LTR-2 (0). 
These results correspond to one representative xperiment out of 
three. Bach value is the average of three measurements. Standard 
deviations were about 10% of the mean for each point. 
Table 1 
Phorbol ester binding in NIH 3T3 cells expressing PKC-I 
Cell line [3H]PDBu binding 
(pmol/106 cells) 
Increase 
25-91 80 + 19 
25-41 170 + 32 2.1 x 
25-89 90 * 70 
25-61 246 + 26 2.7 x 
Cell lines transfected with the p&-y constructs pAC20 (25-41) and 
pAC24 (25-61) were assayed for phorbol 12,13 dibutyrate (PDBu) 
binding activity and compared to cells transfected with the respective 
vectors CIX-I (25-91) and LTR-2 (25-89). All assays are means f 
S.D. of triplicate determinations as described in section 2. The in- 
crease in binding activity refers to the appropriate comparison with 
the controi transfectants 
Table 2 
Cloning efficiency of NIH 3T3 cells overproducing PKC 
TPA (nMl 25-61 25-89 
0 2.7 j: 1.3 3.8 rt 1.2 
10 5.5 + I.7 3.5 * 1.2 
20 6.8 f: 1.9 5.9 f 1.5 
50 17.4 + 2.6 8.8 f 1.9 
100 19.3 f 2.7 13.4 f 2.4 
200 21.5 f 2.7 13.0 f 2.2 
Cell line 25-61 containing plasmid pAC24 and control transfectant 
containing vector LTR-2 were compared for their colony forming ef- 
ficiencies in semisolid medium with and without TPA treatment. 
Values are mean + SD 
trations of TPA, pAC24 transfectants generated up to 
twice as many small colonies in soft agar as the control 
cell population. Thus, the level of PKC expression in 
the pkc-y transfectants was sufficient to cause a pro- 
nounced effect on growth in soft agar but only in the 
presence of TPA. 
4. DISCUSSION 
Our data show that introduction of PKC-I in NIH 
3T3 cells, which normally do not express this PKC sub- 
type, can lead to pronounced changes in mitogenicity 
and anchorage-independent growth upon stimulation 
with the tumor promoter TPA, whereas growth in 
serum containing medium is unaltered. We could not 
detect any changes in morphology or cloning efficiency 
in our pkc-y transfectants without the addition of phor- 
bol esters. Persons et al. 1141 have shown that con- 
stitutive expression of the same gene in NIH 3T3 cells 
resulted in subtle changes of morphology and in growth 
to higher saturation densities. The levels of high affinity 
receptors in those cell lines seemed to be in the same 
range or lower than in our overproducer cells. The dif- 
ferent results in both studies might be due to clonal 
variability in the phenotype of NIH 3T3 cells. We, 
therefore, decided to restrict our analysis to mass cell 
populations transfected with the pkc-y constructs and 
selected for the expression of the marker gene. Our 
results demonstrate that a certain level of increased 
PKC expression is not linked to an increase in 
anchorage-independent growth but that a strong tumor 
promoter such as TPA can evoke such a difference. 
The effect of ‘T;PA may be substantially different 
from the action of other activators of PKC such as 
DAG, since TPA is hardly degraded and can exert a 
more prolonged action on PKC. Thus, chronic stimula- 
tion with TPA results in the degradation of PKC [5]. 
Therefore, the combined short- and long-term action of 
TPA on PKC might be responsible for the observed 
phenotypic changes in cells with originally higher en- 
zyme levels. Nothing is known about the existence of 
specific, in vivo activators for the various subspecies of 
the enzyme. Such physiological activators might exert a 
dual action in vivo similar to the one of TPA in vitro 
and therefore might play an important role in tumour 
growth and dissemination. Cell lines overproducing 
PKC at moderate levels such as those described here 
might be ideal tools to be used in the search for these ac- 
tivators. 
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